Get the Stockscreener App
1.26
0.80%
0.01
Metavia Inc stock is traded at $1.26, with a volume of 51,517.
It is up +0.80% in the last 24 hours and down -17.65% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
See More
Previous Close:
$1.25
Open:
$1.24
24h Volume:
51,517
Relative Volume:
0.22
Market Cap:
$6.41M
Revenue:
-
Net Income/Loss:
$-12.97M
P/E Ratio:
-0.2254
EPS:
-5.5898
Net Cash Flow:
$-15.70M
1W Performance:
-4.55%
1M Performance:
-17.65%
6M Performance:
-88.34%
1Y Performance:
-92.56%
1-Day Range:
$1.20
$1.29
1-Week Range:
$1.17
$1.3393
52-Week Range:
$1.17
$23.10
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.26 | 6.41M | 0 | -12.97M | -15.70M | -5.5898 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
[POS AM] MetaVia Inc. SEC Filing - Stock Titan
MTVA Stock Price, Quote & Chart | METAVIA INC (NASDAQ:MTVA) - ChartMill
1,896,385 Common Stock of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
29,514 Restricted Stock Units of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Market Trends: Can MetaVia Inc continue delivering strong returnsMarket Risk Analysis & Smart Swing Trading Alerts - baoquankhu1.vn
MTVA PE Ratio & Valuation, Is MTVA Overvalued - Intellectia AI
MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026… - scr.zacks.com
Portfolio Shifts: Can MetaVia Inc stock outperform in a bear market2026 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
MetaVia stock price target lowered to $20 by H.C. Wainwright - Investing.com UK
Bearish Setup: Is now the right time to enter MetaVia IncMarket Movers & Fast Gaining Stock Reports - baoquankhu1.vn
Buy Signal: Is now the right time to enter MetaVia IncQuarterly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Can MetaVia Inc stock outperform in a bear marketWeekly Gains Summary & Smart Swing Trading Alerts - baoquankhu1.vn
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution - Investing.com
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution By Investing.com - Investing.com India
Big Picture: Does MetaVia Inc outperform in volatile markets2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
MTVA News | METAVIA INC (NASDAQ:MTVA) - ChartMill
MetaVia Updates Investor Strategy for Obesity and MASH - TipRanks
MetaVia Reports Positive 2025 Financial Results and Advances DA-1726 & Vanoglipel Clinical Programs for Obesity and MASH - Minichart
MTVA: Promising obesity and MASH therapies advance with strong early data and major market potential - TradingView
MTVA: Strong clinical progress in obesity and MASH with robust pipeline and solid financial footing - TradingView
MetaVia (MTVA) updates March 2026 corporate investor presentation - Stock Titan
MetaVia (MTVA) 2025 Financial Update - AlphaStreet
MetaVia Inc 2025 Annual Report: Clinical Progress, Risk Factors, and Cardiometabolic Drug Pipeline Overview - Minichart
MetaVia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MetaVia Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MetaVia: Cash position adequate to fund operations into 4Q26 - TipRanks
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update - The AI Journal
Metavia Reports Year End 2025 Financial Results And Provides Corporate Update - TradingView
MetaVia (NASDAQ: MTVA) highlights progress in MASH and obesity trials - Stock Titan
MTVA: Strong clinical progress and improved financials position the pipeline for key 2026 milestones - TradingView
MetaVia (Nasdaq: MTVA) trims 2025 loss, extends cash and advances obesity drug - Stock Titan
Aug Macro: Does MetaVia Inc outperform in volatile markets2026 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
MetaVia Inc expected to post a loss of $1.24 a shareEarnings Preview - TradingView
S P Trends: What is the target price for MetaVia Inc stock2026 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Price Action: Will MetaVia Inc outperform its industry peers2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Recap Report: What is the target price for MetaVia Inc stock2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
MetaVia receives IRB approval for Phase 1 Part 3 trial of DA-1726 By Investing.com - Investing.com South Africa
MetaVia receives IRB approval for Phase 1 Part 3 trial of DA-1726 - Investing.com Australia
MetaVia Advances DA-1726 GLP-1/Glucagon Dual Agonist for Obesity With IRB Approval for Higher-Dose Phase 1 Trial - Minichart
MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3 - TipRanks
MetaVia gets IRB approval to start Phase 1 Part 3 trial of DA-1726; dosing in April, data due Q4 2026 - TradingView
MetaVia (NASDAQ: MTVA) advances DA-1726 obesity program with IRB-approved higher-dose Phase 1 trial - Stock Titan
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control - PR Newswire
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel - Indian Pharma Post
MTVA: Lead asset achieves rapid weight loss and liver benefits; pivotal data due by year-end - TradingView
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 - PR Newswire
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
US Market Wrap: Can MetaVia Inc continue delivering strong returns2025 Technical Overview & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - ChartMill
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Metavia Inc Stock (MTVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | 10% Owner |
May 08 '25 |
Buy |
0.71 |
4,647,887 |
3,300,000 |
9,995,679 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):